Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
Loryn J. Bohne, Hailey J. Jansen, Tristan W. Dorey, et al.
JACC Basic to Translational Science (2023) Vol. 8, Iss. 8, pp. 922-936
Open Access | Times Cited: 25

Showing 25 citing articles:

Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis
Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3749-3756
Closed Access | Times Cited: 17
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
David Bode, Julius Ryan D. Pronto, Gabriele G. Schiattarella, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 10, pp. 682-700
Closed Access | Times Cited: 16
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation
Danish Iltaf Satti, Alexander Karius, Jeffrey Shi Kai Chan, et al.
JACC. Clinical electrophysiology (2024) Vol. 10, Iss. 8, pp. 1848-1855
Closed Access | Times Cited: 5
Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future
James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, et al.
Medicinal Research Reviews (2024) Vol. 45, Iss. 1, pp. 29-65
Open Access | Times Cited: 4
Atrial Fibrillation Nomenclature, Definitions and Mechanisms:Position Paper from the International Working Group of the Signal Summit
Natasja M.S. de Groot, André G. Kléber, Sanjiv M. Narayan, et al.
Heart Rhythm (2024)
Open Access | Times Cited: 4
Integrated Management of Persistent Atrial Fibrillation
Xindi Yue, Ling Zhou, Chunxia Zhao
Biomedicines (2025) Vol. 13, Iss. 1, pp. 91-91
Open Access
IL-1β enhances susceptibility to atrial fibrillation in mice by acting through resident macrophages and promoting caspase-1 expression
Oscar Moreno-Loaiza, Vinícius Cardoso Soares, M De Souza, et al.
Nature Cardiovascular Research (2025)
Closed Access
Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias
Pegah Bahrami Taqanaki, Kelly A. Aromolaran, Ademuyiwa S. Aromolaran
Journal of Cellular Physiology (2025) Vol. 240, Iss. 2
Open Access
Obesity and Atrial Fibrillation: A Comprehensive Review
Jonathan Na, Sita Sai Garapati, Adi Lador
Methodist DeBakey Cardiovascular Journal (2025) Vol. 21, Iss. 2, pp. 35-43
Closed Access
GLP1R upregulation in mitral regurgitation observed at a single nucleus level
Sameeksha Tiwari, Martin Beyer, Sary F. Aranki, et al.
Journal of Molecular and Cellular Cardiology (2025)
Closed Access
Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights
Aparajita Sarkar, Kareem Fanous, Isra Marei, et al.
Vascular Health and Risk Management (2024) Vol. Volume 20, pp. 255-288
Open Access | Times Cited: 3
Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis
Hongda Zhang, Lei Ding, Ke Liu, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 6, pp. 103067-103067
Closed Access | Times Cited: 2
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
C. Allard, Daniela Cota, Carmelo Quarta
Drugs (2023) Vol. 84, Iss. 2, pp. 127-148
Closed Access | Times Cited: 6
Human Gut Microbiota in Cardiovascular Disease
Daniel Rönen, Y Rokach, Suzan Abedat, et al.
Comprehensive physiology (2024), pp. 5449-5490
Closed Access | Times Cited: 1
New insights into the effects of glucagon-like peptide-1 on heart rate and sinoatrial node function
Simrandeep Kaur, Robert A. Rose
Cardiovascular Research (2024) Vol. 120, Iss. 12, pp. 1367-1368
Closed Access | Times Cited: 1
Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease – insights from the Harmony Outcomes trial
Konstantin A. Krychtiuk, Guillaume Marquis‐Gravel, Shannon Murphy, et al.
European Journal of Preventive Cardiology (2024)
Closed Access | Times Cited: 1
Amiodarone Therapy: Updated Practical Insights
Victoriţa Şorodoc, Lucia Indrei, Catinca Dobroghii, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6094-6094
Open Access | Times Cited: 1
GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?
Lisa Stoll, James C. Lo
JACC Basic to Translational Science (2023) Vol. 8, Iss. 8, pp. 937-938
Open Access | Times Cited: 2
A glükagonszerűpeptid-1-receptor-agonisták cardio- és neuroprotectiv szerepe a 2-es típusú diabetest kísérő ischaemiás stroke előfordulásának mérséklésében
Gábor Winkler, András Folyovich, János Tibor Kis, et al.
Orvosi Hetilap (2024) Vol. 165, Iss. 13, pp. 489-498
Open Access
Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs
Alicja Szołkiewicz-Płatkowska, Michał Orczykowski
In a good rythm (2024) Vol. 4, Iss. 69, pp. 21-25
Closed Access
Stellate ganglion, inflammation, and arrhythmias: a new perspective on neuroimmune regulation
Qiulian Lei, Zefei Jiang, Yu Shao, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action
Bykova Aa, Maria Serova, Maria Chashkina, et al.
Cardiac failure review (2024) Vol. 10
Open Access
Atrial Fibrillation Management with Guideline-Directed Medical Therapy and Comorbidity Treatment in Heart Failure Patients
Alvise Del Monte, Andrea Sarkozy, Frederik H. Verbrugge
Cardiac Electrophysiology Clinics (2024) Vol. 17, Iss. 1, pp. 63-73
Closed Access
Human Gut Microbiota in Cardiovascular Disease
Daniel Rönen, Y Rokach, Suzan Abedat, et al.
Comprehensive physiology (2024) Vol. 14, Iss. 3, pp. 5449-5490
Closed Access
Non-antiarrhythmic Drugs with Antiarrhythmic Properties
Alina Scridon, Andreea Ivanescu, Vasile-Bogdan Halațiu
(2024), pp. 227-282
Closed Access
Page 1

Scroll to top